Brucella crassa of a recombinant Chlamydia psittaci outer membrane protein MOMP gene and its vaccine production method

A technology of Chlamydia psittaci and Brucella, applied in the field of veterinary biological products, can solve the problems of animal reproduction and production performance hazards, difficult to cure, etc., to reduce immunization costs and labor costs, long-term pathogenicity, and high costs Effect

Active Publication Date: 2022-04-26
CHINA INST OF VETERINARY DRUG CONTROL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This disease not only has serious harm to the reproduction and production performance of animals, but more importantly, after people are infected with Brucella, it is often difficult to cure, thus causing serious public health problems.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Brucella crassa of a recombinant Chlamydia psittaci outer membrane protein MOMP gene and its vaccine production method
  • Brucella crassa of a recombinant Chlamydia psittaci outer membrane protein MOMP gene and its vaccine production method
  • Brucella crassa of a recombinant Chlamydia psittaci outer membrane protein MOMP gene and its vaccine production method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] According to the analysis of the whole genome and gene function prediction of Brucella RA343 (CGMCC No.8886, ZL201410240895.6), three molecular chaperone promoters P1, P2, P3, and respectively insert the Brucella promoter P 1 ,P 2 ,P 3 And common promoters tac, trc, T7, construct six green fluorescent plasmids carrying different promoters P 1 -GFP-pZL1790,P 2 -GFP-pZL1790,P 3 - GFP-pZL1790, tac-GFP-pZL1790, trc-GFP-pZL1790, and T7-GFP-pZL1790. They were electrotransferred into the Brucella RA343 strain, and the suitable strong promoter P for exogenous gene expression was selected by the relative expression level of green fluorescent protein. 3 .

[0031] (2) By adding P 3 Codon optimization was performed on the promoter and MOMP sequence, the gene fragment was artificially synthesized, and a P 3 -MOMP sequence and the sucrose suicide plasmid vector pUC / P of Brucella upstream and downstream homology arms 3 -MOMP + , the expression frame of the outer membrane pr...

Embodiment

[0046] The following examples are to further illustrate the present invention, but not to limit the present invention.

[0047] Embodiment 1 - the construction of recombinant Brucella RA343-MOMP strain

[0048] 1. Preparation of Brucella RA343 Competent Cells

[0049] Pick a single inoculated colony of Brucella RA343 strain, inoculate it with 100ml TSB medium and cultivate it until the logarithmic phase of bacterial growth, and cool it in ice water. Centrifuge at 12000r / min for 10min, discard the liquid medium, and wash repeatedly several times with different volumes of sterile deionized water. Finally, the obtained bacteria were resuspended in 1 ml of 10% glycerol aqueous solution, and the prepared parent strain RA343 infected bacteria were stored at -80°C for future use.

[0050] 2. Screening of promoters for exogenous gene expression in Brucella RA343

[0051] (1) Construction of green fluorescent plasmid GFP-pZL1790

[0052] The pZL1790 plasmid is preserved by our labo...

Embodiment 2

[0100] Embodiment 2——The routine biological characteristic of recombinant Brucella RA343-MOMP strain

[0101] 1. Morphological and biochemical properties

[0102] The colonies of recombinant bacteria have neat, rounded edges, dew drop shape, irradiated by oblique light, and slightly blue opalescent in backlight observation. The staining form is cocci, scattered individually, without forming spores and capsules. The size is between 0.3 and 0.6 μm. Gram stain was negative. The growth of the bacteria is independent of CO 2 , can grow on the medium containing thionine and basic fuchsin, H 2 S test was strongly positive.

[0103] 2. Thermal agglutination test

[0104]Inoculate the recombinant strain in TSA medium, culture at 37°C for 46 hours, then take the culture and put it into a test tube filled with about 100ml of normal saline, shake it well, and make it turbid to 1 billion / ml of viable bacteria. Suspension, the taken out bacterial suspension was divided into 2 tubes, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the construction of a recombinant brucella brucella of the outer membrane protein MOMP gene of chlamydia psittaci (Cps) and a vaccine thereof. In the present invention, the attenuated Brucella bovis attenuated strain RA343 is used as the parent strain, and the sucrose suicide plasmid is used as the carrier, and the MOMP gene of the outer membrane protein of Chlamydia psittaci containing a specific promoter sequence is seamlessly inserted into the In the Brucella genome, a recombinant Brucella RA343‑MOMP strain capable of highly expressing the outer membrane protein MOMP gene of Chlamydia psittaci was successfully constructed. The recombinant strain not only retains the rough characteristics of the original parent strain RA343, but also has good immune protection against brucellosis (brucellosis), and after the recombinant strain immunizes animals, it can produce MOMP antibodies against Chlamydia psittaci, thereby achieving Immunoprotection against Chlamydia psittaci. The vaccine prepared by using the recombinant vaccine strain can simultaneously realize double immune protection against brucellosis and Chlamydia psittaci after immunizing animals.

Description

[0001] Technical field [0002] The invention relates to a Brucella crassa strain of recombinant Chlamydia psittaci outer membrane protein MOMP gene and a vaccine production method thereof, belonging to the field of veterinary biological products. [0003] technical background [0004] Brucellosis (brucellosis) is a zoonotic disease characterized by abortion and fever caused by Brucella, which seriously threatens the lives and health of humans and various animals. This disease not only has serious harm to the reproduction and production performance of animals, but more importantly, people are often difficult to cure after being infected with Brucella, thus causing serious public health problems. Elimination of brucellosis has therefore been one of the most important goals of public health programs in countries where Brucella is endemic. At present, the main method to eliminate the disease worldwide is the combination of culling and immunization. For China, where the occurrence...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/10A61K39/118A61P31/04C12N15/31C12N15/74C12N1/21C12R1/01
Inventor 丁家波范学政朱良全冯宇彭小薇秦玉明王芳许冠龙李秋辰蒋卉
Owner CHINA INST OF VETERINARY DRUG CONTROL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap